Compare Citius Pharmaceuticals Inc (CTXR) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while First Trust NASDAQ 100 Technology Index Fund trades at $315.63. The key difference: First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | QTEC | |
|---|---|---|
Market Cap | $18.73M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $335.74 |
52-Week Low | $0.48 | $207.03 |
Enterprise Value | $14.95M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
QTEC trades at $316.59, up 1.7% with a bullish technical signal from moving averages. The ETF, tracking NASDAQ-100 technology stocks, lacks disclosed P/E and P/S ratios. A small dividend of $0.03 is scheduled for June 2026, with support at $313 and resistance at $319.
Outlook remains positive due to strong technical momentum, though overbought RSI signals caution. Risks include tech sector volatility and reliance on broad market trends. Analyst coverage highlights its role for diversified tech exposure without specific ratings available.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
